UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
  • Purpose: to determine if a study drug called recombinant tissue plasminogen activator (rt-PA), which dissolves blood clots, can help to improve a patient's condition regarding brain blood clots by rapidly removing the clot from the ventricles when compared to placebo (a fluid that does not dissolve blood clots)
  • Eligibility: patients ages 18-80 that are admitted with an intraventricular hemorrhage (bleeding in the ventricles or open spaces inside the brain).
  • Duration and Involvement: subjects will receive the study medication while they are hospitalized for their hemorrhage. They will be contacted by phone at 3 and 9 months, and follow up in clinic at 30 days, 6 months, and 1 year (final visit) after enrollment into the study.
Start Date
August 31, 2012
End Date
February 28, 2014
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Harold P. Adams, Jr., MD
Contact Info

Heena Olalde, RN, MSN

Clear III study ; Neurology ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.